Eurosets, an Italian company from Medolla
(in the province of Modena), specialised in the design, production and marketing
of biomedical devices, has been awarded with the Global New Product Innovation
2021 award by Frost & Sullivan for ECMOLife, an innovative device for the
ECMO therapies capable of temporarily replacing the function of the heart and
lungs.
"Every year Frost & Sullivan
awards companies that have distinguished themselves in the field of innovation
worldwide – comments Antonio Petralia, CEO of Eurosets –. The Best Practices
award that is recognised to ECMOLife as the most innovative product in the biomedical
sector testifies to the value of the work done so far and is the confirmation
of having taken the right path. We have leveraged the research and development
of cutting-edge technology, devising an innovative product that allows us to
support the work of healthcare professionals in helping patients in critical
conditions, bringing concrete advantages, and which has allowed, in this period
of the global pandemic, to save many lives."
The Frost & Sullivan Best Practices
awards are a recognition of those companies that, in regional and global
markets, have distinguished themselves for having achieved excellent results in
areas, such as leadership, technological innovation, customer service and
strategic product development. Industry analysts compare various companies in
the market and measure performance through interviews, analysis and in-depth
research.
The Frost & Sullivan award, therefore,
recognises the characteristics and advantages of the product, identifying
ECMOLife as an innovative device in which to invest.
ECMOLife is a "life-saving"
device that currently boasts a very wide range of uses, in fields such as
Cardiac Surgery and Haemodynamics, in Intensive Care, in the treatment of
critical Covid patients, in the case of cardiogenic shock following heart
surgery, to counteract respiratory crises or as a support during lung and
cardiac transplants. It, therefore, allows to stabilise patients in different
therapeutic areas, including extracorporeal membrane oxygenation (ECMO) and
mechanical circulatory support (MCS), in therapies used to treat, for example,
patients with ventricular insufficiency, cardiac arrest or respiratory failure,
patients with acute respiratory tract distress syndrome (ARDS), H1N1, SARS, or
suffering from Covid-19 infections.
The design of ECMOLife includes
cutting-edge technologies for an optimal biocompatibility, from the magnetic
levitation pump to minimise hemolysis, to the use of circuits treated in
Phosphorylcholine to reduce platelet consumption, all elements that testify to
the attention to the patient. ECMOLife is also designed to maximise patient
safety: the non-invasive sensor system allows an effective monitoring, the
integrated back-up guarantees the operation of the device in any situation and
the external batteries allow additional autonomy, with an easier management on
the part of the doctors. Finally, versatility is another feature that
distinguishes ECMOLife: the compact design makes it easy to transport and makes
it portable and flexible, both outside the hospital, to stabilise patients who
need to be transported to the facility, and for the handling of the patient
within the hospital premises.
"The ECMOLife system, with its optimal
biocompatibility, guarantees the patient a perfusion comparable to the native
one. It is one of the few devices currently available on the market to be
enabled for both hospital use and for out-of-hospital transport – comments
Srinath Venkatasubramanian, Transformational Health & Industry Analyst at
Frost & Sullivan –. ECMOLife is extremely versatile and, thanks to its
compact design, is a device applicable in different clinical settings with
great ease. In spite of being only recently introduced, ECMOLife is already
used in 60 hospitals around the world. With the right product and an excellent
presence on the market, Eurosets has all the potential to grow rapidly by
expanding the clinical indications for the use of ECMO."
With over 40 international patents, Eurosets has
been identified by Frost & Sullivan as the leading company in the sector of
biomedical devices for ECLS/ECMO. ECMOLife is, in fact, present in hospitals in
15 countries around the world. To date, more than 400 patients have been
treated with ECMOLife and, "thanks to this state-of-the-art technology, we
have the possibility to increase the chances of recovery and to reduce the
mortality rates in case of cardiac shock or severe respiratory diseases, also
caused from Covid-19”, concludes Petralia.
